SCHEMBL5778141

SCHEMBL5778141

CC(=O)Oc1ccccc1-c1nc2ccccc2c(=O)o1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C1R P00736 7/20 0.73
MAPT P10636 4/20 0.62
ALDH1A1 P00352 3/20 0.62
LMNA P02545 2/20 0.62
PKM P14618 1/20 0.60
NPC1 O15118 5/20 0.59
RAB9A P51151 4/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
HSP90AA1 P07900 1/20 0.59
F2 P00734 2/20 0.58
PLG P00747 1/20 0.58
KLK1 P06870 1/20 0.58
PRSS1 P07477 1/20 0.58
C1S P09871 1/20 0.58
ATM Q13315 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ELANE P08246 3/20 0.54
TP53 P04637 1/20 0.53
KDM4E B2RXH2 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5778170 0.86 PKM (0.64) C1RMAPTALDH1A1LMNAPKM
SCHEMBL5781524 0.86 C1R (0.55) C1RMAPTALDH1A1LMNAPKM
SCHEMBL5921548 0.86 C1R (0.55) C1RMAPTALDH1A1LMNAPKM
SCHEMBL5921076 0.86 C1R (0.65) C1RMAPTALDH1A1LMNAPKM
SCHEMBL5921400 0.86 ALDH1A1 (0.69) C1RMAPTALDH1A1LMNAPKM
SCHEMBL17254720 0.86 CD74 (0.67) C1RMAPTALDH1A1LMNAPKM
SCHEMBL5779985 0.85 ELANE (0.77) C1RMAPTALDH1A1LMNAPKM
SCHEMBL5921767 0.85 C1R (0.63) C1RMAPTALDH1A1LMNAPKM
SCHEMBL30366271 0.85 C1R (1.00) C1RMAPTALDH1A1LMNANPC1
SCHEMBL692226 0.85 C1R (1.00) C1RMAPTALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558260-A4 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMA INC (US) 2006-10-25 EP disclosed
US-20060052345-A1 Quinazolinone compounds as calcilytics NPS PHARMACEUTICALS, INC. (US) 2006-03-09 US disclosed
CN-1708306-A Quinazolinone compounds as calcilytics NPS PHARMA INC (US) 2005-12-14 CN disclosed
EP-1558260-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2005-08-03 EP disclosed
WO-2004041755-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052345-A1 Quinazolinone compounds as calcilytics CALCR, CALCRL, CASR C1R 1605/4885MAPT 4420/4885ALDH1A1 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.